Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer
The results suggest that trastuzumab as adjuvant therapy for early breast cancer may be cost effective when given over either 52 or 9 weeks at current acquisition costs in Australia. However, the overall budget impact of the 52-week course is significant, and the 9-week course appears economically attractive. </AbstractSection> Copyright Adis Data Information BV 2007
Year of publication: |
2007
|
---|---|
Authors: | Millar, J. ; Millward, Michael |
Published in: |
PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 25.2007, 5, p. 429-442
|
Publisher: |
Springer |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
The production of Zn from ZnO in a two-step solar process utilizing FeO and Fe3O4
Millar, J., (1997)
-
Lehmann, William Christian, (1960)
-
The origin of the distinction of ranks
Millar, John, (1986)
- More ...